株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

OpportunityAnalyzer:ブドウ膜炎 - 機会分析と予測

OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017

発行 GlobalData 商品コード 292823
出版日 ページ情報 英文 199 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
OpportunityAnalyzer:ブドウ膜炎 - 機会分析と予測 OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017
出版日: 2013年12月30日 ページ情報: 英文 199 Pages
概要

ブドウ膜炎の治療薬市場は、生物学的製剤の導入だけでなく、投与経路の多様化も伴い、2012年〜2017年の間は成長すると予測されています。

当レポートでは、ブドウ膜炎の治療薬市場について調査分析し、疾患の概要、疫学、現在の治療選択肢、アンメットニーズ分析、機会分析、研究開発戦略、パイプライン評価などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理学
  • 症状

第4章 疫学

  • 危険因子と併存疾患
    • 喫煙は、ブドウ膜炎のリスクを高め、合併症のリスクも上昇させる
    • 若年性突発性関節炎(JIA)患者は、定期的な眼科検診が必須
    • HLA陽性抗原は、特定の種類のブドウ膜炎に関係
    • ブドウ膜炎は、様々な自己免疫性・神経系・伝染性の疾患に関連
  • 世界の動向
    • 米国
    • EU5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:発症件数
    • 予測の前提条件と手法:有病件数
    • 予測の前提条件と手法:病因・解剖学的分布
    • 予測の前提条件と手法:疾患の経過
    • 予測の前提条件と手法:疾患の重症度
  • 疫学予測
    • 発症件数
    • 年齢別発症件数
    • 性別発症件数
    • 年齢調整発症率
    • 発症件数:解剖学的部位別
    • 発症件数:病因別
    • 発症件数:疾患の経過別
    • 発症件数:重症度別
    • 有病件数
    • 年齢別有病件数
    • 性別有病件数
    • 有病件数:解剖学的部位別
    • 有病件数:病因別
  • 議論
    • 疫学予測の考察
    • 分析の限界
    • 分析の強み

第5章 現在の治療選択肢

  • 概要
  • 製品プロファイル:主要ブランド

第6章 アンメットニーズ評価と機会分析

  • 概要
  • アンメットニーズ分析
  • 機会分析

第7章 研究開発(R&D)戦略

  • 概要
  • 臨床試験設計

第8章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬
  • 革新的な初期段階のアプローチ

第9章 パイプライン評価分析

  • 主要パイプライン薬の臨床ベンチマーク
  • 主要パイプライン薬の商業ベンチマーク
  • 競合評価
  • 売上の5ヶ年予測
    • 米国
    • EU5ヶ国

第10章 付録

図表

目次
Product Code: GDHC008POA

Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immunosuppressive and biologic drugs. Since the conventional corticosteroid treatment is only effective in 50-60% of patients a significant number of patients can be targeted with the new treatment options. While anterior uveitis patients represent the majority of patients, all but one of the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. The uveitis market is expected to grow between 2012 and 2017, due to the introduction of biologic drugs as well as a diversification of administrative routes. Market growth is created by the increase in treatment costs and will continue beyond the forecasted time period. The new treatments will target some key unmet needs but opportunities will remain for drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile.

Highlights

Key Questions Answered

  • The uveitis market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the uveitis market?
  • The late-stage uveitis pipeline is filled with diverse molecules and routes of administration. Which drug will have a significant impact on the uveitis market. Which of these drugs will have the highest CAGR, and why?
  • The current uveitis market is dominated by corticosteroids as well as off-label immunosuppressive and biologic drugs. How will the introduction of biologic drugs change the treatment landscape once reimbursement is not a problem anymore? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?

Key Findings

  • The main driver of the expansion of the uveitis market will be the introduction of biologic drugs, which will increase the market size significantly. The introduction of new ocular administration routes will strengthen the market growth further.
  • An additional driver for the uveitis market is the assignment of orphan drug status to several uveitis drugs.
  • The biggest barrier for the introduction of the more costly treatment options like biologics will be reimbursement especially in the European markets. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.
  • Pipeline drugs developed by small to mid-size pharma companies represent a good opportunity for companies to enter the uveitis market and to strengthen their ophthalmology department.

Scope

  • Overview of uveitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized uveitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for five years to 2017.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the uveitis therapeutics market.
  • Pipeline analysis: focus on the five late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global uveitis therapeutics market from 2012-2017.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Important Cytokines for the Pathogenesis of Uveitis and Their Role in Emerging Treatments
    • 3.1.2. Uveitis and Systemic Diseases
    • 3.1.3. Prognosis and Diagnosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. Smoking increases the risk of uveitis and increases its complications
    • 4.1.2. Juvenile idiopathic arthritis patients need regular ophthalmologic screenings
    • 4.1.3. HLA-positive antigens are linked to certain types of uveitis
    • 4.1.4. Uveitis is associated with various autoimmune, neurological, and infectious diseases
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Sources Not Used
    • 4.3.3. Forecast Assumptions and Methods, Incident Cases
    • 4.3.4. Forecast Assumptions and Methods, Prevalent Cases
    • 4.3.5. Forecast Assumptions and Methods, Etiological and Anatomical Distribution
    • 4.3.6. Forecast Assumptions and Methods, Course of the Disease
    • 4.3.7. Forecast Assumptions and Methods, Disease Severity
  • 4.4. Epidemiological Forecast for Uveitis (2012-2022)
    • 4.4.1. Incident Cases of Uveitis
    • 4.4.2. Age-Specific Incident Cases of Uveitis
    • 4.4.3. Sex-Specific Incident Cases
    • 4.4.4. Age-Standardized Incidence Rates
    • 4.4.5. Incident Cases by Primary Anatomical Location of Inflammation
    • 4.4.6. Incident Cases Segmented by Etiology
    • 4.4.7. Incident Cases by Course of Disease
    • 4.4.8. Incident Cases by Severity of Disease
    • 4.4.9. Prevalent Cases of Uveitis
    • 4.4.10. Age-Specific Prevalent Cases of Uveitis
    • 4.4.11. Sex-Specific Prevalent Cases of Uveitis
    • 4.4.12. Prevalent Cases by Primary Anatomical Location of Inflammation
    • 4.4.13. Prevalent Cases by Etiology
  • 4.5. Discussion
    • 4.5.1. Epidemiological Forecast Insight
    • 4.5.2. Limitations of the Analysis
    • 4.5.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Retisert (Fluocinolone acetonide)
    • 5.2.2. Ozurdex (Dexamethasone Acetate)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Therapy to maintain vision and control inflammation
    • 6.2.2. Drugs with fewer adverse events
    • 6.2.3. Increased number of approved and reimbursed treatments
    • 6.2.4. Less frequent and more efficient treatment for anterior uveitis patients
    • 6.2.5. Development of a non-corticosteroid ocular implant
    • 6.2.6. Education of physicians and improved treatment guidelines
  • 6.3. Opportunity Analysis
    • 6.3.1. A drug that is able to maintain vision
    • 6.3.2. A drug with an improved side effect profile

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Uveitis as an Add-On Indication
    • 7.1.2. Uveitis as a First Indication for a New Drug
    • 7.1.3. Development of Ophthalmic Routes of Administration
  • 7.2. Clinical Trial Design

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Humira (adalimumab)
    • 8.2.2. EGP-437 (dexamethasone acetate)
    • 8.2.3. Xoma 052 (gevokizumab)
    • 8.2.4. DE-109 (sirolimus)
    • 8.2.5. Medidur (fluocinolone acetonide)
  • 8.3. Innovative Early-Stage Approaches

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmarks of Key Pipeline Drugs
  • 9.2. Commercial Benchmarks of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4 Forecast Methodology
    • 10.4.1. Diagnosed and Treated Uveitis Patients
    • 10.4.2. Uveitis: Course of Disease
    • 10.4.3. Uveitis: Severity
    • 10.4.4. Drugs Included in Each Therapeutic Class
    • 10.4.5. Launch and Patent Expiry Dates
    • 10.4.6. General Pricing Assumptions
    • 10.4.7. Individual Drug Assumptions
    • 10.4.8. Generic Erosion
    • 10.4.9. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Epidemiologist
    • 10.6.3. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Anatomic Classification of Uveitis
  • Table 2: Disease Course of Uveitis
  • Table 3: Cytokines and Their Significance in Uveitis
  • Table 4: Systemic Diseases Associated with Uveitis
  • Table 5: Prognosis for Uveitis Patients
  • Table 6: Symptoms and Ocular Comorbidities Associated with Uveitis
  • Table 7: Diseases Most Frequently Associated with Uveitis
  • Table 8: Distribution of Uveitis by Anatomical Location in Community and Referral Centers
  • Table 9: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe
  • Table 10: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location of Inflammation
  • Table 11: SUN/IUSG Clinical Classifications of Uveitis
  • Table 12: 6MM, Sources of Data for the Incidence and Prevalence of Uveitis in the 6MM
  • Table 13: Italy, Uveitis Anatomical Distribution Calculation
  • Table 14: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases
  • Table 15: 6MM, Incident Cases of Uveitis, N (Column %), Select Years, 2012-2022
  • Table 16: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012
  • Table 17: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012
  • Table 18: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %), 2012
  • Table 19: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012
  • Table 20: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012
  • Table 21: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012
  • Table 22: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012
  • Table 23: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012-2022
  • Table 24: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012
  • Table 25: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012
  • Table 26: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012
  • Table 27: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012
  • Table 28: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012
  • Table 29: Overview of the Most Common Uveitis Treatments
  • Table 30: New Treatments for Uveitis
  • Table 31: Product Profile - Retisert
  • Table 32: Retisert SWOT Analysis
  • Table 33: Product Profile - Ozurdex
  • Table 34: Ozurdex SWOT Analysis
  • Table 35: Overall Unmet Needs - Current Level of Attainment
  • Table 36: Uveitis - Late Stage Pipeline, 2012
  • Table 37: Product Profile - Humira
  • Table 38: Humira SWOT Analysis
  • Table 39: EGP-437 Product Profile
  • Table 40: EGP-437 SWOT Analysis
  • Table 41: Xoma 052 Product Profile
  • Table 42: Xoma 052 SWOT Analysis
  • Table 43: DE-109 Product Profile
  • Table 44: DE-109 SWOT Analysis
  • Table 45: Medidur Product Profile
  • Table 46: Medidur SWOT Analysis
  • Table 47: Early-Stage Pipeline Products in Uveitis
  • Table 48: Clinical Benchmarks of Pipeline Biologics
  • Table 49: Clinical Benchmarks of Pipeline Ocular Implants
  • Table 50: Clinical Benchmarks of Pipeline Topical Corticosteroids
  • Table 51: Clinical Benchmark of Pipeline Ocular Injections
  • Table 52: Commercial Benchmarks of Pipeline Ocular Implants
  • Table 53: Commercial Benchmark of PipelineTopical Corticosteroids
  • Table 54: Commercial Benchmark of Pipeline Ocular Injections
  • Table 55: Top-Line Sales Forecast ($) for Uveitis, 2012-2017
  • Table 56: Key Events Impacting Sales for Uveitis in the US and EU, 2012-2017
  • Table 57: US and EU Uveitis Markets, Drivers and Barriers, 2012-2017
  • Table 58: Key Launch Dates
  • Table 59: Key Patent Expiries

List of Figures

  • Figure 1: Anatomy of the Eye
  • Figure 2: Underlying Mechanism of Autoimmune Uveitis
  • Figure 3: US, Age Distribution of the Study Populations Compared with the US General Population
  • Figure 4: US, Sex Ratio of the Study Populations Compared with the US General Population
  • Figure 5: 6MM, Incident Cases of Uveitis, N, Select Years, 2012-2022
  • Figure 6: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012
  • Figure 7: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012
  • Figure 8: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women, 2012
  • Figure 9: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012
  • Figure 10: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012
  • Figure 11: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012
  • Figure 12: 6MM, Prevalent Cases of Uveitis, N, Select Years, 2012-2022
  • Figure 13: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012
  • Figure 14: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012
  • Figure 15: Current Treatment of Uveitis
  • Figure 16: Competitive Assessment of Late-Stage Pipeline Agents in Uveitis, 2012-2017
  • Figure 17: Global Sales for Uveitis by Country, 2012-2017
Back to Top